Accolade Is Maintained at Equal-Weight by Wells Fargo
Accolade Is Maintained at Equal-Weight by Wells Fargo
Wells Fargo: Maintaining the Accolade (ACCD.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $12.00 to $10.00.
Wells Fargo: Maintaining the Accolade (ACCD.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $12.00 to $10.00.
Wells Fargo Maintains Equal-Weight on Accolade, Lowers Price Target to $10
Wells Fargo analyst Stan Berenshteyn maintains Accolade (NASDAQ:ACCD) with a Equal-Weight and lowers the price target from $12 to $10.
Accolade, Inc.'s (NASDAQ:ACCD) Latest 14% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Key Insights Significantly high institutional ownership implies Accolade's stock price is sensitive to their trading actions 54% of the business is held by the top 8 shareholders Analyst forecast
EDIT, CLNE and NIU Are Among After Hour Movers
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Aon plc (NYSE:AON) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Aon posted adjusted earnings of $5.66 per share, missing ma
Earnings Call Summary | Accolade(ACCD.US) Q4 2024 Earnings Conference
The following is a summary of the Accolade, Inc. (ACCD) Q4 2024 Earnings Call Transcript:Financial Performance:Accolade Inc. reported Q4 revenue of $125 million, a 30% pro forma growth over the same p
Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating
Accolade (ACCD) has an average rating of outperform and price targets ranging from $10 to $18, according to analysts polled by Capital IQ. Price: 7.92, Change: -1.27, Percent Change: -13.82
12 Health Care Stocks Moving In Friday's Intraday Session
GainersBiodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 61.4% to $1.17 during Friday's regular session. The company's market cap stands at $5.1 million. Agenus (NASDAQ:AGEN) shares rose 32.53% to $11.
Accolade Price Target Cut to $11.00/Share From $13.00 by Barclays
Accolade Price Target Cut to $11.00/Share From $13.00 by Barclays
Barclays: Maintaining the Accolade (ACCD.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $13.00 to $11.00.
Barclays: Maintaining the Accolade (ACCD.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $13.00 to $11.00.
Accolade Is Maintained at Buy by Needham
Accolade Is Maintained at Buy by Needham
Needham Maintains Buy on Accolade, Lowers Price Target to $13
Needham analyst Ryan MacDonald maintains Accolade with a Buy and lowers the price target from $17 to $13.
Barclays Remains a Hold on Accolade (ACCD)
Accolade Inc (ACCD) Q4 2024 Earnings Call Transcript Highlights: Record Revenue and Strategic ...
Accolade Inc (ACCD) Surpasses Revenue Expectations and Narrows Losses in Fiscal Q4 and Full ...
MXL, COLM and SPSC Are Among After Hour Movers
Accolade Sees Q1 Revenue $103M-$106M Vs $110.86M Est., FY24 Revenue $480M-$500M Vs $413.5M Est.
Accolade Sees Q1 Revenue $103M-$106M Vs $110.86M Est., FY24 Revenue $480M-$500M Vs $413.5M Est.
Accolade (ACCD.US): The 2024 Q4 financial report achieved revenue of US$124.8 million, with a previous value of US$99.025 million, with an expected value of US$123.9 million; earnings per share were -0.10 dollars, the previous value was -0.42 dollars, and
Accolade (ACCD.US): The 2024 Q4 financial report achieved revenue of US$124.8 million, with a previous value of US$99.025 million, with an expected value of US$123.9 million; earnings per share were -0.10 dollars, the previous value was -0.42 dollars, and the expected value was -0.07 dollars.
Accolade Q4 2024 GAAP EPS $(0.10) Beats $(0.12) Estimate, Sales $124.831M Beat $123.915M Estimate
Accolade (NASDAQ:ACCD) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 76.19 percent increase over losses of $(0.42) per
No Data